LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders
Rhea-AI Summary
LakeShore Biopharma (OTCPK: LSBCF / LSBWF) has called an extraordinary general meeting of shareholders for February 12, 2026 at 11:00 a.m. Beijing time to vote on a previously announced Agreement and Plan of Merger dated November 4, 2025 with Oceanpine Skyline Inc. If approved, Merger Sub will merge into LakeShore and the company will become a wholly owned subsidiary of Parent and a privately held company.
Upon closing, the company’s ordinary shares and warrants will no longer be quoted on any public marketplace (including OTC Pink) and will cease to be registered under Section 12 of the Securities Exchange Act. Shareholders of record as of 5:00 p.m. Cayman Islands time on January 16, 2026 may vote. Relevant filings include the Schedule 13E-3 and definitive proxy statement filed with the SEC.
Positive
- Board and independent special committee provided a unanimous recommendation to approve the Merger
- Merger will convert LakeShore into a wholly owned subsidiary of Oceanpine Skyline
Negative
- Company ordinary shares and warrants will no longer be quoted on public markets, including OTC Pink
- Company Shares and Company Warrants will cease to be registered under Section 12 of the Securities Exchange Act
News Market Reaction – LSBCF
On the day this news was published, LSBCF declined 0.29%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers with momentum data were recorded; recent price behavior around LSBCF appeared stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Nasdaq delisting | Negative | -3.4% | Update on Nasdaq delisting and transition to OTC Pink trading status. |
| Nov 04 | Going-private agreement | Positive | +12.4% | Definitive merger agreement to take company private at a cash premium. |
Recent news-driven moves aligned with the tone of each announcement, with both major events showing price reactions consistent with their sentiment.
Over the past few months, LakeShore Biopharma has transitioned from a Nasdaq-listed issuer to trading on the OTC Pink tier, following a delisting determination highlighted in news on Sep 11, 2025 and an update on Nov 18, 2025. On Nov 4, 2025, the company announced a definitive going-private merger agreement. Today’s EGM notice fits into that process, outlining the shareholder vote needed to finalize the previously disclosed transaction.
Market Pulse Summary
This announcement advanced LakeShore Biopharma’s previously disclosed going-private deal by scheduling an EGM on February 12, 2026 to vote on the merger agreement. Earlier news outlined key terms, including a US$0.90 per-share cash consideration and implied US$37 million equity value. Investors may focus on the required shareholder approvals, prior delisting history, and the transition to private ownership when evaluating the company’s trajectory.
Key Terms
warrants financial
Schedule 13E-3 regulatory
proxy statement regulatory
AI-generated analysis. Not financial advice.
Pursuant to the Merger Agreement and the Plan of Merger, at the effective time of the merger, Merger Sub will be merged with and into the Company and cease to exist, with the Company being the surviving company and becoming a wholly owned subsidiary of Parent. If consummated, the merger will result in the Company becoming a privately held company, and its ordinary shares, par value
The Company's board of directors, acting upon the unanimous recommendation of a special committee of independent directors established by the board of directors, authorized and approved the execution, delivery and performance of the Merger Agreement, the Plan of Merger and the consummation of the transactions contemplated thereby, and resolved to recommend that the Company's shareholders vote FOR, among other things, the proposal to authorize and approve the Merger Agreement, the Plan of Merger, and the consummation of the transactions contemplated thereby, including the merger.
Shareholders of record as of 5 p.m.
Additional information regarding the EGM and the Merger Agreement can be found in the transaction statement on Schedule 13E-3 and the definitive proxy statement attached as Exhibit (a)-(1) thereto, as amended, filed with the
SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.
The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be "participants" in the solicitation of proxies from the shareholders with respect to the proposed merger. Information regarding the persons who may be considered "participants" in the solicitation of proxies is set forth in the Schedule 13E-3 transaction statement relating to the proposed merger and the definitive proxy statement attached thereto. Further information regarding persons who may be deemed participants, including any direct or indirect interests they may have, is also set forth in the definitive proxy statement.
This announcement is for information purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any securities or a solicitation of any proxy, vote or approval with respect to the proposed transaction or otherwise, nor shall it be a substitute for any proxy statement or other filings that have been or will be made with the SEC.
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in
For more information, please visit https://investors.lakeshorebio.com/.
Forward-Looking Statements
This press release contains statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company's business plans and development, which can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "future," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. LakeShore Biopharma may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about LakeShore Biopharma's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: uncertainties as to how the Company's shareholders will vote at the meeting of shareholders; the possibility that events may arise that result in the termination of the Merger Agreement; the possibility that competing offers will be made; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 and the proxy statement filed by the Company; the Company's goals and strategies; the Company's future business development, financial condition and results of operations; its ability to provide efficient services and compete effectively; its ability to maintain and enhance the recognition and reputation of its brands; general economic and business conditions globally and in
For investor inquiries, please contact:
IR Team
Tel: +86 (10) 8920-2086
Email: ir@lakeshorebio.com
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-to-hold-extraordinary-general-meeting-of-shareholders-302665312.html
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
When is LakeShore Biopharma's (LSBCF) extraordinary general meeting to vote on the merger?
What will happen to LSBCF shares and warrants if the Oceanpine merger is approved?
Who is entitled to vote at the LakeShore (LSBCF) EGM and what is the record date?
Did LakeShore's board recommend the merger with Oceanpine Skyline (LSBCF)?
Where can investors find the definitive proxy statement and Schedule 13E-3 for LSBCF?
Will LSBCF become a private company if shareholders approve the merger?
